Generic Zomig and Vfend Launched by Ajanta Pharma

Ajanta Pharma Limited has been given final approval from the FDA to launch zolmitriptan tablets, 2.5 mg and 5 mg, and voriconazole tablets, 50 mg and 200 mg.

Ajanta Pharma Limited has been given final approval from the FDA to launch zolmitriptan tablets, 2.5 mg and 5 mg, and voriconazole tablets, 50 mg and 200 mg.

The zolmitriptan tablets may be used for the acute treatment of migraines, and it is the bioequivalent generic version of Zomig, which is marketed by Impax Pharmaceuticals.

The most common adverse effects associated with zolmitriptan include nausea, pain, tingling sensation, and unusual taste. However, some individuals may also have an increased risk of heart attacks, high blood pressure, and stroke.

Two days after the approval of the zolmitriptan tablets, Ajanta announced that it had also received FDA approval for its voriconazole tablets, which are a generic version of Pfizer’s Vfend. Patients can use Ajanta’s generic version to treat serious invasive fungal infections.

Visual disturbances, fever, nausea, rash, vomiting, chills, headache, tachycardia, and hallucinations are some of the potential adverse effects associated with voriconazole.

To date, the FDA has granted 9 abbreviated new drug application final approvals and 2 tentative approvals to Ajanta Pharma Limited.